Globes [online] is reporting that Neurosonix Ltd., a Or-Yehuda, Israel company, has received a $12 million infusion of venture capital to implement its embolism diversion technology by ultrasound. Company’s website does not give many details on how the technology works, but here’s what Globes [online] says about their product:
Neurosonix has developed a device intended to prevent coronary embolisms from reaching the brain where they may be lethal. The device is based on ultrasound technology, which diverts the embolism from the arteries leading to the brain, in a non-invasive manner, and prevents them from reaching the dangerous area. The ultrasound is placed outside the arteries, inside the open chest cavity, above the aorta, and creates waves which divert embolisms out of the arteries leading to the brain and back into the body. This is done without disrupting the flow of blood to the brain.
According to Neurosonix website, its technology will be developed as a disposable transducer called EmBlocker™, to be used on full thoracotomy cases, off and on bypass. It also seems that the company is working on implementing its technology–for now called the Protection Collar–for catheterization procedures as well.
Article at Globes [online]…
Company website…